Lead Inventor:
Gregg G. Gundersen, Ph.D.
Cancer therapy to prevent metastasis:
As the incidence of cancer continues to rise, additional therapeutic technologies are needed more than ever. Current adjuvant therapies inject hormones, antibodies, or other peptides into the patient; however, these therapeutics are expensive to manufacture and do not always prevent metastasis (the spread of the cancer to other parts of the body.) Novel and more cost-effective classes of cancer therapeutic strategies are critical for improved prevention of metastasis that results in the spread of cancer.
Nucleic acid cancer therapy inhibtis metastasis, scar fromation and inflammation:
This technology utilizes a cost-effective and cutting-edge nucleic acid therapeutic strategy (RNAi) to inhibit EB1 protein expression. EB1 inhibition prevents cell migration, a key step in metastasis and the spread of cancer throughout the body. This technology can also be used to inhibit scar formation and inflammation following physical trauma in a patient.
Applications:
• Inhibition of cell metastasis and the spread of cancer throughout the body
• Inhibition of scar formation in a subject following the affliction of physical trauma
• Reduction of inflammation in a subject
Advantages:
• Novel nucleic acid segment that inhibits EB1 and cell migration
• Can be used to treat a number of conditions including cell metastasis, scar formation, and inflammation
• Nucleic acid therapeutic production more cost-effective than traditional peptide therapeutics
Patent Status: Patent Pending (
US 20070148663)
Publications:
Nature Cell Biology, September 2004, 6(9):820-30.
Licensing Status: Available for Licensing and Sponsored Research Support